• Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Life Sciences British Columbia

  • Newsletters |
  • Members Area |
  • Contact
  • SearchSearch
  • About
    • Board of Directors
    • Management
    • Vision & Mission
  • Awards
  • Membership
    • Sponsors
    • Members Directory
    • Members Area
    • Membership Benefits
    • Membership Discounts
    • Members Services
    • Members Map
    • Become a Member
  • Events
    • Calendar
    • Webinars
    • Past Events
      • 2023 Events
      • 2022 Events
      • 2021 Events
      • 2020 Events
      • 2019 Events
      • 2018 Events
  • News
    • All News
    • Member News
    • Industry News
    • LSBC in The News
    • Publications
    • BC Labour Market Study
  • Resources
    • All Resources
    • Grants and Funding
      • Funding Competitions
      • Wage Subsidies
    • Academic Institutions
    • Government
      • Federal
      • Provincial and Municipal
    • Association Partners
    • Programs
    • Volunteering
  • Jobs
    • Job Board
    • Post a Job
    • Career Events
  • Contact Us
  • Login
Home » All News » Takeda Receives Prestigious Prix Galien Canada Innovative Product Award for TAKHZYRO® (lanadelumab)

All News

  • Member News
  • Industry News
  • LSBC in The News
Member News

Takeda Receives Prestigious Prix Galien Canada Innovative Product Award for TAKHZYRO® (lanadelumab)

November 21, 2022
Takeda Canada Inc.

TORONTO, ON — Takeda Canada Inc. (“Takeda”) is pleased to announce that TAKHZYRO® (lanadelumab), the first approved monoclonal antibody for the treatment of Hereditary Angioedema (HAE) has been named the 2022 winner of the prestigious Prix Galien Canada Innovative Product Award. The most prestigious award in the field of Canadian pharmaceutical research and innovation, Prix Galien Canada recognizes the efforts and achievements of pharmaceutical research and development. The annual award was presented at a gala ceremony in Toronto on November 15, 2022.

“We are honoured TAKHZYRO has received the Prix Galien Canada 2022 Innovative Product Award, and are even more proud of the tremendous impact it’s had on HAE patients in Canada,” said Rute Fernandes, General Manager of Takeda Canada Inc. “This prestigious award is a reflection of Takeda’s dedication and commitment to bring innovative treatments to patients.”

About Hereditary Angioedema (HAE)

Hereditary Angioedema or HAE is a rare genetic condition that impacts about 1 in 50,000 people worldwide. HAE involves recurrent attacks of severe swelling (angioedema) in various parts of the body, including the hands, feet, genitals, stomach, face and/or throat. Symptoms of HAE usually appear early in life, most often by age 13, and may increase in severity after puberty. When untreated, an HAE attack often lasts for three days, sometimes even longer, and many people with HAE experience three or more swelling attacks per month.i

About the Prix Galien Canada

The Prix Galien is the most prestigious award in the field of Canadian pharmaceutical research and innovation. Referred to as the Nobel Prize of pharmaceutical research, it recognizes the efforts and achievements of pharmaceutical research and development. The Prix Galien Canada is administered by Innovation Life Canada. https://www.prix-galien-canada.com/

About Takeda Canada Inc.

Takeda Canada Inc. is the Canadian organization of Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK), a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discovering and delivering life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit:  takeda.com/en-ca 

Media Contacts:
Amanda Jacobs
amanda.jacobs@takeda.com
+1 647-798-2231

Original source here.

Primary Sidebar

  • Category:

  • Sector:

  • Archives:

© 2023 Life Sciences BC  |  Privacy Policy

  • Current Jobs
  • Event Calendar
  • All News
  • Member Directory
    Connect with us
  • LinkedIn
  • Twitter
  • Facebook
  • Instagram
Contact Us